News Releases

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Month Year

Su	Mo	Tu	We	Th	Fr	Sa
25	26	27	28	29	30	1
2	3	4	5	6	7	8
9	10	11	12	13	14	15
16	17	18	19	20	21	22
23	24	25	26	27	28	29
30	31	1	2	3	4	5

Cancel Go

Email Alerts

Year All Years 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005 2004 2003 2002 Keywords Go

Advanced Search

Keywords

  Search Headlines Only

From

To

Asset Types

 Photos  Video  Audio  Documents  Events  Standard

 Basic Search

• Jun 8, 2020

  Insmed Receives FDA Breakthrough Therapy Designation for Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis (NCFBE)

  --Full Results from Phase 2 WILLOW Study of Brensocatib in NCFBE to be Presented at Virtual ATS Session on June 24, 2020--
• Jun 5, 2020

  Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
• May 26, 2020

  Insmed to Present at Two June Conferences
• May 20, 2020

  Insmed to Showcase New Brensocatib Data at American Thoracic Society Virtual Clinical Trials Session

  -Results from Phase 2 WILLOW Study of Brensocatib in Patients with Non-Cystic Fibrosis Bronchiectasis to be Presented-
• May 7, 2020

  Insmed Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Show 5102550100 per page

Stay In The Loop

Want to stay up to date on our news, events, and filings? Set up your
email alerts.

Sign Up

View the latest Insmed Investor Presentation

Download